Catalyst Pharmaceuticals Stock (NASDAQ: CPRX)

Catalyst Pharmaceuticals Stock (NASDAQ:CPRX), Trade Ideas

Catalyst Pharmaceuticals

Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.

News

Short Ideas

Small Cap

Pre-Market Outlook

Markets

Trading Ideas

CPRX

SILK

As of Feb. 29, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Top 3 Health Care Stocks You May Want To Dump In Q1

Media

CBSH

On CNBC’s &#34;Mad Money Lightning Round,&#34; Jim Cramer said  Stanley Black &amp; Decker, Inc.

Jim Cramer Likes This Bank &#39;Very, Very Much,&#39; Says Stock Is Up 7% Over Past 6 Months

Penny Stocks

Intraday Update

Movers

AIMD

ALLO

ANGO

APLT

ATXI

AXGN

BNZI

CISO

CYCC

DRMA

ELAN

EXAI

IMCR

Intelligent Bio Solutions Inc. - Common Stock

INBS

KORE

KRUS

LSDI

NEXI

OMGA

PNST

PTON

PYPD

RCAC

SABS

SMFL

SWVL

TBPH

VERB

VYGR

Why Applied Therapeutics Shares Are Trading Lower By Over 35%? Here Are Other Stocks Moving In Friday&#39;s Mid-Day Session

Catalyst Pharmaceuticals, Inc. - Common Stock

Catalyst Pharmaceuticals Inc

<p>7 analysts have expressed a variety of opinions on Catalyst Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRX#NASDAQ">CPRX</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $29.29, with a high estimate of $34.00 and a low estimate of $23.00. Surpassing the previous average price target of $28.00, the current average has increased by 4.61%.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1711544449_0.png" alt="price target chart" /></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive Catalyst Pharmaceuticals. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leland Gershell</td>
<td>Oppenheimer</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$29.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$34.00</td>
<td>-</td>
</tr>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$34.00</td>
<td>-</td>
</tr>
<tr>
<td>Samantha Semenkow</td>
<td>Citigroup</td>
<td>Announces</td>
<td>Buy</td>
<td>$27.00</td>
<td>-</td>
</tr>
<tr>
<td>Jason Gerberry</td>
<td>B of A Securities</td>
<td>Announces</td>
<td>Buy</td>
<td>$23.00</td>
<td>-</td>
</tr>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Overweight</td>
<td>$34.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$24.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Catalyst Pharmaceuticals. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Catalyst Pharmaceuticals compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for Catalyst Pharmaceuticals's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Catalyst Pharmaceuticals's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/CPRX/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Catalyst Pharmaceuticals analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>About Catalyst Pharmaceuticals</h2>
<p>Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.</p>
<h3>Unraveling the Financial Story of Catalyst Pharmaceuticals</h3>
<p><strong>Market Capitalization Analysis:</strong> With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Catalyst Pharmaceuticals showcased positive performance, achieving a revenue growth rate of <strong>81.98%</strong> as of 31 December, 2023. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> Catalyst Pharmaceuticals's net margin is impressive, surpassing industry averages. With a net margin of <strong>31.51%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Catalyst Pharmaceuticals's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>9.46%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Catalyst Pharmaceuticals's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>7.89%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.01</strong>.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Ratings

Decoding 7 Analyst Evaluations For Catalyst Pharmaceuticals

<p>Oppenheimer  analyst Leland Gershell   reiterates Catalyst Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRX#NASDAQ">CPRX</a>) with a Outperform and maintains $29 price target.</p>


Price Target

Reiteration

Oppenheimer Reiterates Outperform on Catalyst Pharmaceuticals, Maintains $29 Price Target

<p>Cantor Fitzgerald  analyst Charles Duncan   reiterates Catalyst Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRX#NASDAQ">CPRX</a>) with a Overweight and maintains $34 price target.</p>


Cantor Fitzgerald Reiterates Overweight on Catalyst Pharmaceuticals, Maintains $34 Price Target

<p>Citigroup  analyst Samantha Semenkow   initiates coverage on Catalyst Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRX#NASDAQ">CPRX</a>) with a Buy rating and announces Price Target of $27.</p>


Initiation

Citigroup Initiates Coverage On Catalyst Pharmaceuticals with Buy Rating, Announces Price Target of $27

<p><i>AGAMREE&#xAE; (vamorolone) a Novel Alternative Corticosteroid with Demonstrated Properties in Maintaining Efficacy and a Well-Tolerated Side Effect Profile</i><br /><br />&nbsp;</p>
<p><i>Available in the U.S. by Prescription for Patients Aged Two Years and Older</i></p>
<p><i>Catalyst Pathways&#xAE; Program will Support AGAMREE Patients and Available to Help Ensure DMD Patients Affordable Access and Product Education</i></p>
<p>CORAL GABLES, Fla., March 13, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc.&nbsp;("Catalyst") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRX#NASDAQ">CPRX</a>), a commercial-stage biopharmaceutical company, today announced the U.S. commercial launch of AGAMREE&#xAE; (vamorolone) oral suspension 40 mg/mL for the treatment of Duchenne Muscular Dystrophy ("DMD") in patients aged two years and older. Following the U.S. Food and Drug Administration ("FDA") approval on October 26, 2023, <a href="https://www.globenewswire.com/Tracker?data=aBqmHm-ptl3UgV7xR_w5rcONvxFm05zNMU4bWAsnr5LxFB_LVYTcdlNb6b8QtnPGKmFsS8M2LADg0S1ioVcH2w==">AGAMREE</a> is now available by prescription and dispensed throughout the United States through a specialty pharmacy network.</p>
<p>"Today, we proudly announced the U.S. commercial availability of AGAMREE, an innovative alternative steroid treatment for Duchenne Muscular Dystrophy. This significant milestone offers hope for improved quality of life for individuals living with this devastating rare disease, as current steroid treatment options often involve a significant side effect burden," stated Richard J. Daly, CEO of Catalyst. "With the potential to extend ambulation and mobility for patients, AGAMREE marks an important therapeutic advancement with the prospect of reshaping the treatment paradigm for this life-threatening condition. We are firmly positioned to leverage our well-established commercial capabilities for a successful U.S. launch and remain resolute in our mission to help ensure that all patients have access to this novel therapy. Our Catalyst Pathways, a personalized program, is readily available to assist Duchenne Muscular Dystrophy patients and their families with the one‐on‐one education and financial support they need, thereby enhancing the access and affordability of AGAMREE for every patient. We eagerly look forward to collaborating with healthcare providers to facilitate patient access, reinforcing our unwavering dedication to serving our patient communities."</p>
<p><a href="https://www.globenewswire.com/Tracker?data=Fk1lmLcr8qIadcmmeNzwH0NTEERssJBslAuxJB3sEHR-KWtjawn-cjjakj8PLGdNETuOmFA413f1UdvtcBc4Bwn6zXZrJZ9HFWLaBOcoF238iDaEiPb39FbErmehcRkd">Catalyst Pathways</a>&#xAE;&nbsp;Patient Assistance Program for AGAMREE&#xAE; is a comprehensive patient support program that includes a dedicated, personalized support team that assists families throughout the AGAMREE treatment journey for eligible patients. For more information, caregivers and healthcare professionals can call 1-833-422-8259 or visit the Catalyst Pathways&#xAE; website at <a href="https://www.globenewswire.com/Tracker?data=qF5g7_UHdQKXHl9PkgYQcOhIwwSoXvwz_a_Z3P2ttm-9LpgzitC1J3kbmLOZN42zDYy-Iywb7LLO2uw8AWGPYXQ4r1begbojLZj8-qKNC-aC8KgtduB-A_5B_fodSb9z">www.yourcatalystpathways.com</a>.</p>
<p>Duchenne Muscular Dystrophy, DMD, the most common form of muscular dystrophy, is a rare and life-threatening neuromuscular disorder characterized by progressive muscle dysfunction, ultimately leading to loss of ambulation, respiratory failure, and fatality. Current standard treatment for DMD involves corticosteroids, which often come with significant side effects. It is estimated that between 11,000 and 13,000 patients in the U.S. are affected by DMD, with approximately 70% of patients currently receiving a corticosteroid treatment. Steroids are expected to remain the backbone of therapy for DMD patients and dosed concomitantly with other therapies.</p>
<p>The FDA's approval of AGAMREE&#xAE; was based on the data from the pivotal Phase 2b VISION-DMD study as supplemented with safety information collected from three open-label studies, including extension studies. In these trials, AGAMREE was administered at doses ranging from 2 to 6 mg/kg/day, extending for up to 48 months. Compared with current standard-of-care corticosteroids, this novel corticosteroid treatment exhibited comparable efficacy, with data suggesting a reduction in adverse events, notably related to bone health, growth trajectory, and improved behavior.</p>
<p><strong>About AGAMREE&#xAE; (vamorolone)</strong><br /><br />AGAMREE's unique mode of action is based on differential effects on glucocorticoid and mineralocorticoid receptors and modifying further downstream activity. As such, it is considered a novel corticosteroid with dissociative properties in maintaining efficacy that we hope has the potential to demonstrate comparable efficacy to steroids, with the potential for a better-tolerated side effect profile. This mechanism of action may allow AGAMREE to emerge as an effective alternative to the current standard of care corticosteroids in children, adolescents, and adult patients with DMD. In the pivotal VISION-DMD study, AGAMREE met the primary endpoint Time to Stand (TTSTAND) velocity versus placebo (p=0.002) at 24 weeks of treatment and showed a good safety and tolerability profile. The most commonly reported adverse events versus placebo from the VISION-DMD study were cushingoid features, psychiatric disorders, vomiting, weight increases, and vitamin D deficiency. Adverse events were generally of mild to moderate severity.</p>
<p>AGAMREE was granted&nbsp;U.S.&nbsp;FDA approval on&nbsp;October 26, 2023, and has been granted Orphan Drug Exclusivity (ODE) for DMD and New Chemical Entity Exclusivity (NCE) in the&nbsp;U.S., conferring seven years and 5 years of exclusivity, respectively, from the date of approval. AGAMREE also has granted pending patents that could provide protection until 2040. In&nbsp;Europe, it has received Promising Innovative Medicine (PIM) status from the&nbsp;UK&nbsp;MHRA for DMD.</p>


Biotech

General

Catalyst Pharmaceuticals Announces AGAMREE Now Commercially Available In The U.S. For The Treatment Of Duchenne Muscular Dystrophy

<p>In the last three months, 4 analysts have published ratings on Catalyst Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRX#NASDAQ">CPRX</a>), offering a diverse range of perspectives from bullish to bearish.</p>
<p>The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $27.75, a high estimate of $34.00, and a low estimate of $23.00. Surpassing the previous average price target of $27.00, the current average has increased by 2.78%.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1709830852_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>A comprehensive examination of how financial experts perceive Catalyst Pharmaceuticals is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jason Gerberry</td>
<td>B of A Securities</td>
<td>Announces</td>
<td>Buy</td>
<td>$23.00</td>
<td>-</td>
</tr>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Overweight</td>
<td>$34.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$24.00</td>
<td>-</td>
</tr>
<tr>
<td>Leland Gershell</td>
<td>Oppenheimer</td>
<td>Announces</td>
<td>Outperform</td>
<td>$30.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Catalyst Pharmaceuticals. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Catalyst Pharmaceuticals compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>Capture valuable insights into Catalyst Pharmaceuticals's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/CPRX/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Catalyst Pharmaceuticals analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Get to Know Catalyst Pharmaceuticals Better</h2>
<p>Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.</p>
<h3>Catalyst Pharmaceuticals: Financial Performance Dissected</h3>
<p><strong>Market Capitalization Analysis:</strong> Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Catalyst Pharmaceuticals's remarkable performance in 3 months is evident. As of 31 December, 2023, the company achieved an impressive revenue growth rate of <strong>81.98%</strong>. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> Catalyst Pharmaceuticals's net margin excels beyond industry benchmarks, reaching <strong>31.51%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Catalyst Pharmaceuticals's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>9.46%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Catalyst Pharmaceuticals's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>7.89%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> Catalyst Pharmaceuticals's debt-to-equity ratio is below the industry average. With a ratio of <b>0.01</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Assessing Catalyst Pharmaceuticals: Insights From 4 Financial Analysts

<p>B of A Securities  analyst Jason Gerberry   initiates coverage on Catalyst Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRX#NASDAQ">CPRX</a>) with a Buy rating and announces Price Target of $23.</p>


B of A Securities Initiates Coverage On Catalyst Pharmaceuticals with Buy Rating, Announces Price Target of $23

<p>Cantor Fitzgerald  analyst Charles Duncan   maintains Catalyst Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRX#NASDAQ">CPRX</a>) with a Overweight and raises the price target from $27 to $34.</p>


Cantor Fitzgerald Maintains Overweight on Catalyst Pharmaceuticals, Raises Price Target to $34

<p>HC Wainwright &amp; Co.  analyst Andrew Fein   reiterates Catalyst Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRX#NASDAQ">CPRX</a>) with a Buy and maintains $24 price target.</p>


HC Wainwright & Co. Reiterates Buy on Catalyst Pharmaceuticals, Maintains $24 Price Target

<p>As of Feb. 29, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.</p>
<p>The RSI is a momentum indicator, which compares a stock&#39;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#39;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi"> RSI is above 70</a>, according to <a href="https://pro.benzinga.com/"> Benzinga Pro</a>.</p>
<p>Here&rsquo;s the latest list of major overbought players in this sector.</p>
<h3><strong>Avidity Biosciences, Inc. </strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rna#NASDAQ">RNA</a>)</h3>
<ul>
<li>On Feb. 28, Avidity Biosciences posted a wider-than-expected quarterly loss. &quot;With proven delivery of RNA to muscle and robust efficacy and long-term safety data from our ongoing clinical development programs, we are revolutionizing the delivery of RNA with our AOC technology,&quot; said Sarah Boyce, president and chief executive officer at Avidity. &quot;2024 is poised to be a transformative year for Avidity as we plan to initiate the global Phase 3 HARBOR&trade; trial for people living with DM1 and report data from all three of our clinical development programs to treat rare muscle diseases &ndash; DM1, FSHD and DMD44.&quot; The company&rsquo;s stock gained around 25% over the past month and has a <a href="https://www.benzinga.com/quote/RNA"><em>52-week high of $24.84 </em></a>.</li>
<li><strong>RSI Value:</strong> 80.36</li>
<li><strong>RNA Price Action: </strong> Shares of Avidity Biosciences fell 0.3% to close at $15.26 on Wednesday.</li>
</ul>
<h3><strong>Catalyst Pharmaceuticals, Inc. </strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cprx#NASDAQ">CPRX</a>)</h3>
<ul>
<li>On Feb. 28, Catalyst Pharmaceuticals posted better-than-expected quarterly results. &quot;In 2023, Catalyst delivered exceptional financial performance demonstrated by robust revenue growth, exceeding our full-year guidance. Our confidence for continued growth is strengthened by the outstanding execution of our strategic initiatives, expansion of our product portfolio, and a growing commercial presence in the U.S. neuroscience market,&quot; stated Richard J. Daly, CEO of Catalyst. The company&rsquo;s stock gained around 6% over the past five days and <a href="https://www.benzinga.com/quote/CPRX"><em> has a 52-week high </em></a> of $18.22.</li>
<li><strong>RSI Value:</strong> 75.19</li>
<li><strong>CPRX Price Action: </strong> Shares of Catalyst Pharmaceuticals gained 1.5% to close at $14.56 on Wednesday.</li>
</ul>
<h3><strong>Silk Road Medical, Inc </strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/silk#NASDAQ">SILK</a>)</h3>
<ul>
<li>On Feb. 28, Silk Road Medical posted a narrower-than-expected fourth-quarter loss. &ldquo;With the right team in place, broad reimbursement, and extensive evidence in support of TCAR, we are laser focused on deepening adoption in physicians who perform TCAR,&rdquo; said Chas McKhann, CEO of Silk Road Medical. The company&rsquo;s stock gained around 17% over the past month has a <a href="https://www.benzinga.com/quote/SILK"><em> 52-week high </em></a> of $48.44.</li>
<li><strong>RSI Value:</strong> 77.31</li>
<li><strong>SILK Price Action: </strong> Shares of Silk Road Medical gained 1.1% to close at $17.69 on Wednesday.</li>
</ul>
<p>&nbsp;</p>
<p>Read More: <a href="https://www.benzinga.com/news/24/02/37386929/shoals-technologies-posts-weak-q4-results-joins-butterfly-network-schr-dinger-and-other-big-stocks-m"><em> Shoals Technologies Posts Weak Q4 Results, Joins Butterfly Network, Schr&ouml;dinger And Other Big Stocks Moving Lower In Thursday&#39;s Pre-Market Session </em></a></p>


Earnings

Guidance

Catalyst Pharmaceuticals Expects 2024 Total Revenues Between $455M-$475M Vs. $463.19M Consensus

<p>Catalyst Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRX#NASDAQ">CPRX</a>) reported quarterly adjsuted earnings of $0.53 per share which beat the analyst consensus estimate of $0.26 by 103.85 percent. This is a 70.97 percent increase over earnings of $0.31 per share from the same period last year. The company reported quarterly sales of $110.57 million which beat the analyst consensus estimate of $106.12 million by 4.19 percent. This is a 81.98 percent increase over sales of $60.76 million the same period last year.</p>


Catalyst Pharmaceuticals Q4 Adj. EPS $0.53 Beats $0.26 Estimate, Sales $110.57M Beat $106.12M Estimate

<p><strong>Catalyst Pharmaceuticals</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRX#NASDAQ">CPRX</a>) is set to give its latest quarterly earnings report on Wednesday, 2024-02-28. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Catalyst Pharmaceuticals will report an <strong>earnings per share</strong> (EPS) of $0.26. </p>
<p>Catalyst Pharmaceuticals bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Past Earnings Performance</h3>
<p>Last quarter the company beat EPS by $0.05, which was followed by a 1.75% drop in the share price the next day.</p>
<p>Here's a look at Catalyst Pharmaceuticals's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2023</strong></th>
<th><strong>Q2 2023</strong></th>
<th><strong>Q1 2023</strong></th>
<th><strong>Q4 2022</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.44</td>
<td>0.42</td>
<td>0.32</td>
<td>0.21</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.49</td>
<td>0.53</td>
<td>0.41</td>
<td>0.31</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-2.0%</td>
<td>6.0%</td>
<td>-19.0%</td>
<td>10.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1709056916_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of Catalyst Pharmaceuticals were trading at $14.18 as of February 26. Over the last 52-week period, shares are down 7.47%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/CPRX/earnings"><strong>To track all earnings releases for Catalyst Pharmaceuticals visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Earnings Preview For Catalyst Pharmaceuticals

<p>Catalyst Pharmaceuticals, Inc. ("Catalyst") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRX#NASDAQ">CPRX</a>), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases, today announced an upcoming poster about the establishment of a registry to study long-term safety and quality of life (QoL) in patients with Duchenne muscular dystrophy (DMD) who are treated with AGAMREE&#xAE; (vamorolone) at the upcoming 2024 MDA Clinical &amp; Scientific Conference taking place March 3-6 in Orlando.<br /><br />&nbsp;</p>
<p>The poster will detail the establishment of a multicenter, observational, prospective, longitudinal registry at approximately 25 U.S. sites. Investigators will assess the progress of 250 male patients who are at least 2 years old at week 12 and then every 12 months for up to five years. The first interim analysis is expected in May 2025.</p>
<p><strong>Poster Information</strong>:</p>
<p><strong>Title</strong>: An Imminent Registry to Study Long-term Safety and Quality of Life in Patients with Duchenne Muscular Dystrophy treated with Vamorolone (AGAMREE&#xAE;)<br /><br /><strong>Poster Number: </strong>M174</p>
<p>"This registry will provide real-world data regarding long-term use of the novel corticosteroid, generating additional data to the current clinical results and underscoring the potential of AGAMREE&#xAE; to reshape the DMD treatment paradigm with a focus on improving the quality of life for patients," said Gary Ingenito, MD, Ph.D., Chief Medical and Regulatory Officer of Catalyst. "We encourage physicians treating patients with DMD to consider enrolling eligible patients in this registry."</p>
<p>Learn more about #MDAConference here: <a href="https://www.globenewswire.com/Tracker?data=btm_8R1OPojeWQLLhxMIKzbghP26rZH8wwJnBQVB414x0n6tTQG-llxJlA2403O6ijQ5_Dq_RvucWWASTE1zwr5LB2-35b_mht41tvxUSsWlSQwssbiegYP6DqjyMbFg">https://www.mdaconference.org/</a></p>
<p><strong>About AGAMREE&#xAE;&nbsp;(vamorolone)</strong><br /><br />AGAMREE's unique mode of action is based on differential effects on glucocorticoid and mineralocorticoid receptors and modifying further downstream activity. As such, it is considered a novel corticosteroid with dissociative properties in maintaining efficacy that we hope has the potential to demonstrate comparable efficacy to steroids, with the potential for a better-tolerated side effect profile. This mechanism of action may allow vamorolone to emerge as an effective alternative to the current standard of care corticosteroids in children, adolescents, and adult patients with DMD. In the pivotal VISION-DMD study, vamorolone met the primary endpoint Time to Stand (TTSTAND) velocity versus placebo (p=0.002) at 24 weeks of treatment and showed a good safety and tolerability profile. The most commonly reported adverse events versus placebo from the VISION-DMD study were cushingoid features, vomiting, and vitamin D deficiency. Adverse events were generally of mild to moderate severity.</p>
<p>AGAMREE was granted&nbsp;U.S.&nbsp;FDA approval on&nbsp;October 26, 2023, and was granted Orphan Drug and Rare Pediatric Disease designation status for DMD in the&nbsp;U.S., making it eligible for seven years of orphan drug exclusivity upon approval. AGAMREE also has issued and pending patents that could provide protection until 2040. In&nbsp;Europe, it has received Promising Innovative Medicine (PIM) status from the&nbsp;UK&nbsp;MHRA for DMD.</p>
<p>References:<br /><br />[1] Dang UJ et al. (2024) Neurology 024;102:e208112.&nbsp;<a href="https://www.globenewswire.com/Tracker?data=jjxI2FjP_SLjoSWNKQ7xklVEP8d0aybz-VDbr0IbuQMHVbE2JtLYyjqW6SCwx7DUTuBE3LEzqG4pRiyAnTh8Yk7lvlQ6at2ZzWB2UBRRwCMG89USeBmFxjHToNwRkA0o_89q2XVUWudkkkRbzJnAmVXgaq_9M_Y5kQ4gti3zUTo=">doi.org/10.1212/WNL.0000000000208112</a>.&nbsp;<a href="https://www.globenewswire.com/Tracker?data=bB-595-ztcF0pI50AKMAQ2665tHBZYiTEkFutWLZH_HH77naaRxlfX1BUfJOuIYyOGXY9qVJza4mhgI_6cx7vuFyHXZfG9eILKunZsAKuB19Y18YiFg8JIe8rRS9qw3hVGzstm7EYzJ_Ye56c_koSc4D3whfM6CQj0P3hPJg2m5_B3aoVrmBoVicpi83dHhrGA7pGSNWKB9toNQguA4kDHmQTnFcetiX7JAJCS6asUBxRHaGOwLoGM9J2rxFuuGuS3p3MtFVEE9z9ntJu3LI-w==">Link</a>.<br /><br />[2] Guglieri M et al (2022). JAMA Neurol. 2022;79(10):1005-1014. doi:10.1001/jamaneurol.2022.2480.&nbsp;<a href="https://www.globenewswire.com/Tracker?data=bB-595-ztcF0pI50AKMAQ___K2uTJDwfZyOdl19qknuhTnTHu3YArBL76dq9vBPymMqzd56VBN2neUykhC9QicSwRbOCNVTWKxaWrPbgT7nMOoygFmu_MkKUE5Cl738A3tDpAD4795fm6aUtlfYYOmzOpawg6YF062ygkqWOQuMQz6fPsakjStD5ia_QowzggDk0xokEn4MfLBKMXnmPFrf5rfJmCmEfoy0mthikIo0i6xkjAFcotr6l5lZ6GkmG1Sk-4sQI9PVPN1Z5S488DOv96nYMVZzXxrhPArTHieg7-kmBxVSI5wFD_P3K0aZ0aVbMavTkrHMvz0bjVq9uK6laGOQgr-PyOCNP-Gt8C1koqLy2NEeh8C_nqqDPOD_AINnLZ0EJBn-VtDNOIiupwiZvrAsOe4iACbJxmGwcElt-Obeq616ZYdO0L_eeclc4wzVJMxbUaNF5stqcfS4y3w==">Link</a>.<br /><br />[3] Liu X et al. (2020).&nbsp;Proc Natl Acad Sci USA&nbsp;117:24285-24293<br /><br />[4] Heier CR et al (2019). Life Science Alliance DOI: 10.26508<br /><br />[5] Ward et al., WMS 2022, FP.27 - Poster 71. Link.<br /><br />[6] Hasham et al., MDA 2022 Poster presentation. Link.<br /><br />[7] Applicable drug labeling: Summary of Product Characteristics (SmPC).&nbsp;<a href="https://www.globenewswire.com/Tracker?data=cttigBtyCu5bXqQmNRPEKTvWcKVawgZ1Y5zN4hR_QE4i1CwV8JtEkx62feM39FZc73eQW_nA-UAgevNDdzuu2KJM4PWvJEJ379kgApE6yG6uA-STvGqeOIVjfmPAONuRLFNR767-M4j8WcYhbUagP41oR9m1ABezBkJttoA1sEv-mBLhReoye40z6RfnWoXbSFn1Lg-sUVYDWSZPN-w9iYO1DuXBxLProzQas657V4EWN9hBEpCM-yX5uyPrk-L6xG_KABTgHQD34kL-p_1V8CjjXIluwsOwjUpn3vHy3tmy_N287KFVjZXX_cqoQI4hCDlG6xMX8-nZA-2gKqqI940bL72VD9uZLimwpmeMPOc=">English</a>.</p>


Catalyst Pharmaceuticals To Present At MDA Clinical & Scientific Conference Details Of Registry For Study Of Long-Term Safety And Quality Of Life In Duchenne Muscular Dystrophy Patients Treated With AGAMREE

Catalyst Pharmaceuticals Announces Publication Of Santhera Pharmaceutical's VISION-DMD Vamorolone  Study Results In Journal Neurology

<p>On CNBC&rsquo;s &quot;Mad Money Lightning Round,&quot; <strong>Jim Cramer</strong> said <strong> Stanley Black &amp; Decker, Inc. </strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/swk#NYSE">SWK</a>) is &quot;very inexpensive, and if people are buying <strong>Home Depot</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hd#NYSE">HD</a>) and <strong>Loews</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/l#NYSE">L</a>), they should be <a href="https://www.benzinga.com/markets/equities/23/12/36257527/stanley-black-decker-streamlines-portfolio-with-760m-infrastructure-sale-to-epiroc-targets-debt-"> buying Stanley Black &amp; Decker.&quot; </a></p>
<p>&quot;I&rsquo;m not a big fan of the airline stocks,&quot; Cramer said when asked about <strong> American Airlines Group Inc. </strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aal#NASDAQ">AAL</a>). The company is scheduled to report its fourth-quarter and full-year 2023 financial results on Thursday, Jan. 25, 2024.</p>
<p>Cramer recommended to wait &quot;until the Fed cuts rates and autos come back&quot; before buying <strong> ON Semiconductor Corporation </strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/on#NASDAQ">ON</a>).</p>
<p><em>Don&rsquo;t forget to check out our <a href="https://www.benzinga.com/premarket/"> premarket coverage here </a> </em></p>
<p>When asked about <strong> Commerce Bancshares, Inc. </strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cbsh#NASDAQ">CBSH</a>), he said, &quot;I like that bank very, very much.&quot; The company&rsquo;s stock has gained more than 7% over the past six months.</p>
<p>Cramer said he can&rsquo;t recommend <strong> Invesco Mortgage Capital Inc. </strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ivr#NYSE">IVR</a>) as he doesn&rsquo;t know what mortgages they have.</p>
<p>The &quot;Mad Money&quot; host said he needs to do some work on <strong> Catalyst Pharmaceuticals, Inc. </strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cprx#NASDAQ">CPRX</a>). &quot;I do not know Catalyst, so I cannot opine on it,&quot; he added.</p>
<p><strong>Price Action:</strong> Shares of Catalyst Pharmaceuticals fell 1% to close at $14.56, while Invesco Mortgage Capital shares rose 0.6% to $9.05 on Friday. Commerce Bancshares gained 2.9% to settle at $54.53, while ON Semiconductor shares rose 0.9% to close at $73.87 during Friday&rsquo;s session. American Airlines shares fell 1.2% to settle at $13.66, while Stanley Black &amp; Decker gained 0.4% to $94.90 on Friday. Shares of Home Depot gained 1.3%, while Loews rose 1% on Friday.<br />
<em>Now Read This: <a href="https://www.benzinga.com/news/earnings/24/01/36690876/how-to-earn-500-a-month-from-at-t-stock-ahead-of-q4-print"> How To Earn $500 A Month From AT&amp;T Stock Ahead Of Q4 Print </a> </em></p>
<p><em>Image: Shutterstock</em></p>


Jim Cramer Likes This Bank 'Very, Very Much,' Says Stock Is Up 7% Over Past 6 Months

<p>Shares of <strong> Applied Therapeutics, Inc. </strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aplt#NASDAQ">APLT</a>) shares fell sharply during Friday&rsquo;s session after the company released topline results of the ARISE-HF Phase 3 trial of AT-001 (caficrestat) in patients with Diabetic Cardiomyopathy (DbCM) at high risk of <a href="https://www.benzinga.com/general/biotech/24/01/36508058/applied-therapeutics-diabetes-associated-heart-disease-drug-fails-in-phase-3-study-stock-plunges">progression to overt heart failure</a>.</p>
<p>The study&#39;s primary endpoint was stabilization or improvement in cardiac functional capacity as measured by Peak VO2 in patients treated with AT-001 1500mg twice daily (BID) compared to placebo.</p>
<p>Applied Therapeutics shares dipped 35.6% to $2.4498 on Friday.</p>
<p>Here are some other stocks moving in today&#39;s mid-day session.</p>
<h3><strong>Gainers</strong></h3>
<ul>
<li><strong>Ainos, Inc.</strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aimd#NASDAQ">AIMD</a>) jumped 112.6% to $3.6805 after falling more than 12% on Thursday.</li>
<li><strong>Revelstone Capital Acquisition Corp.</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rcac#NASDAQ">RCAC</a>) shares climbed 89.6% to $10.71. Revelstone Capital Acquisition cancelled special meeting to approve business combination with Set Jet, Inc.</li>
<li><strong>Banzai International, Inc. </strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bnzi#NASDAQ">BNZI</a>) surged 74% to $2.92. Banzai International signed a non-binding letter of intent to acquire IGLeads, a cutting-edge automated lead generation platform.</li>
<li><strong>Safe and Green Development Corporation </strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sgd#NASDAQ">SGD</a>) shares rose 56.5% to $2.1307. Safe And Green Development recently issued an update on LOI for acquisition of Xene AI Software platform.</li>
<li><strong>NexImmune, Inc.</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nexi#NASDAQ">NEXI</a>) gained 30% to $7.67</li>
<li><strong>Dermata Therapeutics, Inc. </strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/drma#NASDAQ">DRMA</a>) rose climbed 27.8% to $0.78 after the company announced the issuance of a new patent in Japan for its DMT410 program for the treatment of hyperhidrosis.</li>
<li><strong>Polished.com Inc.</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pol#NYSE">POL</a>) gained 27.2% to $8.05.</li>
<li><strong>Swvl Holdings Corp.</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/swvl#NASDAQ">SWVL</a>) gained 27.2% to $2.90.</li>
<li><strong>PolyPid Ltd.</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pypd#NASDAQ">PYPD</a>) gained 25% to $8.44. PolyPid announced $16.2 million private placement of 3,371,312 shares at $4.81 per share.</li>
<li><strong>AxoGen, Inc.</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/axgn#NASDAQ">AXGN</a>) jumped 20.4% to $8.13 as the company reported preliminary unaudited revenue for fourth quarter and full-year 2023. The company also said President and Chief Executive Officer Karen Zaderej plans to retire from the Company by Jan. 2025.</li>
<li><strong>Aurora Mobile Limited</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/jg#NASDAQ">JG</a>) jumped 19.2% to $3.79.</li>
<li><strong>Kura Sushi USA, Inc.</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/krus#NASDAQ">KRUS</a>) rose 15.7% to $86.31 following first-quarter results.</li>
<li><strong>The Greenbrier Companies, Inc.</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gbx#NYSE">GBX</a>) gained 13.8% to $50.50 following upbeat earnings.</li>
<li><strong>Peloton Interactive, Inc.</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pton#NASDAQ">PTON</a>) rose 13.1% to $6.93.</li>
<li><strong>Pinstripes Holdings Inc. </strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pnst#NYSE">PNST</a>) shares gained 12.4% to $5.92 after dipping over 35% on Thursday.</li>
<li><strong>Cyclacel Pharmaceuticals, Inc.</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cycc#NASDAQ">CYCC</a>) rose 12.4% to $2.53.</li>
<li><strong>Elanco Animal Health Incorporated</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/elan#NYSE">ELAN</a>) gained 8% to $15.72. Stifel analyst Jonathan Block upgraded Elanco Animal Health from Hold to Buy and raised the price target from $13 to $20.</li>
<li><strong>Intelligent Bio Solutions Inc.</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/inbs#NASDAQ">INBS</a>) shares rose 7.2% to $0.3212 after falling around 5% on Thursday. Intelligent Bio Solutions recently received National Association of Testing Authorities accreditation for its Intelligent Fingerprinting Drug Screening Solution.</li>
</ul>
<h3><strong>Losers</strong></h3>
<ul>
<li><strong>agilon health, inc.</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/agl#NYSE">AGL</a>) tumbled 35.1% to $7.84 after the company lowered its 2023 financial outlook.</li>
<li><strong>Avenue Therapeutics, Inc.</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/atxi#NASDAQ">ATXI</a>) shares fell 33.7% to $0.2266. Avenue Therapeutics shares jumped over 94% on Thursday after the company announced it reached a final agreement with the FDA for the Phase 3 safety study for IV tramadol.</li>
<li><strong>Medical Properties Trust, Inc.</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mpw#NYSE">MPW</a>) fell 30.6% to $3.4699 after it disclosed plans to reduce its exposure to tenant Steward Health Care System. Keybanc analyst Austin Wurschmidt downgraded Medical Properties Trust from Overweight to Sector Weight.</li>
<li><strong>AngioDynamics, Inc.</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ango#NASDAQ">ANGO</a>) dipped 22.6% to $6.00 after the company lowered its FY24 guidance.</li>
<li><strong>Lucy Scientific Discovery Inc.</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lsdi#NASDAQ">LSDI</a>) fell 22% to $0.1949.</li>
<li><strong>Voyager Therapeutics, Inc. </strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vygr#NASDAQ">VYGR</a>) fell 19.1% to $8.77. Voyager Therapeutics priced its public offering of 7,777,778 common shares at $9 per share.</li>
<li><strong>Verb Technology Company, Inc. </strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/verb#NASDAQ">VERB</a>) shares fell 17.4% to $0.1340. On Dec. 29, Verb Technology Company entered into a securities purchase agreement with Streeterville Capital where company sold and investor purchased 3,000 shares of the company&#39;s newly designated non-convertible Series C preferred stock for $3 million.</li>
<li><strong>KORE Group Holdings, Inc.</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/kore#NYSE">KORE</a>) shares fell 14.8% to $1.04 after jumping over 60% on Thursday.</li>
<li><strong>Allogene Therapeutics, Inc.</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/allo#NASDAQ">ALLO</a>) shares declined 14.1% to $2.9050. Allogene Therapeutics and Foresight Diagnostics disclosed a partnership to develop MRD-based in-vitro diagnostic for use in ALPHA3, the first pivotal trial for frontline consolidation in large B-cell lymphoma. JMP Securities and Guggenheim downgraded the stock.</li>
<li><strong>Omega Therapeutics, Inc.</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/omga#NASDAQ">OMGA</a>) declined 13.8% to $4.58.</li>
<li><strong>CISO Global Inc. </strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ciso#NASDAQ">CISO</a>) shares fell 13.7% to $0.0901. CISO Global said the Nasdaq has determined to delist securities from Nasdaq.</li>
<li><strong>Catalyst Pharmaceuticals, Inc.</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cprx#NASDAQ">CPRX</a>) shares fell 13.4% to $14.81 after announcing pricing of public offering of common stock.</li>
<li><strong>Smart for Life, Inc. </strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/smfl#NASDAQ">SMFL</a>) shares fell 12.3% to $1.6408 after jumping around 15% on Thursday.</li>
<li><strong>Exscientia plc</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/exai#NASDAQ">EXAI</a>) fell 10.8% to $5.84. B of A Securities analyst Michael Ryskin downgraded Exscientia from Buy to Neutral and lowered the price target from $11 to $9.</li>
<li><strong>SAB Biotherapeutics, Inc.</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sabs#NASDAQ">SABS</a>) tumbled 9.1% to $5.90.</li>
<li><strong>Sabine Royalty Trust</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/sbr#NYSE">SBR</a>) fell 8.7% to $63.02.</li>
<li><strong>Dyne Therapeutics, Inc.</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dyn#NASDAQ">DYN</a>) shares fell 8% to $17.84. Dyne Therapeutics priced its $300 million public offering of 17.15 million common stock at $17.50 per share.</li>
<li><strong>Immunocore Holdings plc</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/imcr#NASDAQ">IMCR</a>) dipped 7.3% to $64.61. Immunocore announced strategic priorities and pipeline expansion ahead of 42nd Annual J.P. Morgan Healthcare Conference presentation.</li>
<li><strong>Theravance Biopharma, Inc.</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tbph#NASDAQ">TBPH</a>) shares fell 6.6% to $10.76 after the company announced results from Phase 4 YUPELRI PIFR-2 study. The company said study did not show a statistically significant difference between yupelri and spiriva handihaler on primary endpoint.</li>
</ul>
<p>Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/01/36509097/insiders-buying-synchronoss-technologies-and-2-other-stocks"><em> Insiders Buying Synchronoss Technologies And 2 Other Stocks</em></a></p>


Why Applied Therapeutics Shares Are Trading Lower By Over 35%? Here Are Other Stocks Moving In Friday's Mid-Day Session

WIIM

Catalyst Pharmaceuticals shares are trading lower after the company announced a $150 million public offering of 10 million of its common stock at a price of $15 per share.

<p><strong>Catalyst Pharmaceuticals Inc</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cprx#NASDAQ">CPRX</a>) shares are trading lower by 13% to $14.89&nbsp;Friday morning. The company announced the pricing of a public offering of 10 million shares of its common stock at $15.00 per share, resulting in total gross proceeds of <a href="https://www.benzinga.com/pressreleases/24/01/g36508369/catalyst-pharmaceuticals-inc-announces-pricing-of-public-offering-of-common-stock">$150 million</a>.</p>
<p>The underwriters have a 30-day option to purchase an additional 1.5 million shares. The offering, expected to close around January 9&nbsp;is led by bookrunners <strong>BofA Securities</strong>, <strong>Citigroup</strong>, <strong>Piper Sandler &amp; Co.</strong>, <strong>Cantor</strong>&nbsp;and <strong>Truist Securities</strong>.</p>
<p>Catalyst intends to use the net proceeds for potential new product candidate acquisitions and general corporate purposes.</p>
<p><em>See Also:&nbsp;<a href="https://www.benzinga.com/economics/macro-economic-events/24/01/36509119/december-jobs-report-topples-expectations-robust-payroll-wage-growth-jeopardize-f">December Jobs Report Topples Expectations</a></em></p>
<p>According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, CPRX has a 52-week high of $22.11&nbsp;and a 52-week low of $11.09.</p>


Why Catalyst Pharmaceuticals Stock Is Trading Lower

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Belite Bio, Inc. ADR (BLTE – Research Report), Catal...

Analysts' Top Healthcare Picks: Belite Bio, Inc. ADR (BLTE), Catalyst Pharma (CPRX)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on REPRO-MED Systems (KRMD – Research Report), Catalyst...

Analysts' Top Healthcare Picks: REPRO-MED Systems (KRMD), Catalyst Pharma (CPRX)

Citi starts Catalyst at buy, cites rare disease drug portfolio

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>Why do you want to consider <a href="https://investorplace.com/industries/healthcare/biotech/">biotech stocks</a>? Simply, the narrative comes down to numbers and a possible rotation.</p>



<p>First, the hard data supports bullishness in biotech stocks. According to Grand View Research, the underlying global industry <a href="https://www.grandviewresearch.com/industry-analysis/biotechnology-market">reached a valuation of $1.55 trillion</a> last year. Moving forward, experts project that the sector will expand at a compound annual growth rate (CAGR) of 13.96% from 2024 to 2030. At the culmination point, the space may be worth $3.88 trillion.</p>



<p>Second, a sector rotation may be underway. Yes, artificial intelligence remains a hot topic. However, after a blistering run among several AI-related enterprises, last week showed a possible slowing of momentum. However, traders might not be ready to call it a day. Rather, they&rsquo;d be looking for new opportunities.</p>



<p>What could be better than technology designed to help people? Below are biotech stocks to consider.</p>



<h2>Bio-Techne (TECH)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/10/biotechnology1600-300x169.png" alt="Biotechnology stocks, biomedical stocks"><div>Source: aslysun / Shutterstock.com</div></div><p>Based in Minneapolis, Minnesota, <strong>Bio-Techne</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/tech-stock-quote/"><strong>TECH</strong></a>) develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic and bioprocessing markets. While not exactly a pure-play example among biotech stocks, Bio-Techne represents an important cog in the overall ecosystem. Since the start of the year, TECH slipped 5%.</p>



<p>Part of the problem is that the company&rsquo;s recent financial performances have been lackluster. In the third quarter of last year, Bio-Techne posted earnings per share of 41 cents, missing the 43-cent target. For Q4, it posted an EPS of 40 cents, below the 41-cent estimate. Further, for the current fiscal year, analysts see sales only reaching $1.15 billion, just 1% higher from 2023&rsquo;s result.</p>



<p>However, in 2025, they anticipate revenue of $1.25 billion. If so, that would represent almost 9% year-over-year growth. Still, if the anticipated sector rotation occurs early, there&rsquo;s no reason why TECH shouldn&rsquo;t rise sooner.</p>



<p>Covering experts rate TECH stock a <a href="https://www.tipranks.com/stocks/tech/forecast">consensus strong buy</a> with an $81.50 price target.</p>



<h2>Centessa Pharmaceuticals (CNTA)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/02/medical-biotech-stocks1600-300x169.png" alt="Healthcare business graph data and growth, Medical examination and doctor analyzing medical report network connection on tablet screen. VANI stock"><div>Source: PopTika / Shutterstock.com</div></div><p>Based in the U.K., <strong>Centessa Pharmaceuticals</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/cnta-stock-quote/"><strong>CNTA</strong></a>) discovers, develops, and delivers medicines to patients. Specifically, it focuses on an activated protein C inhibitor for the <a href="https://finance.yahoo.com/quote/CNTA/profile">treatment of hemophilia A and B</a>. As well, it&rsquo;s working on an orally administered drug for the treatment of <a href="https://centessa.com/pipeline/">narcolepsy type 1 (NT1)</a>. Since the start of the year, CNTA gained almost 34%.</p>



<p>Part of the investment thesis for Centessa centers on its momentum. Over the past 52 weeks, shares gained nearly 169% of equity value. Basically, the company is attempting to recover from a disappointing public market debut back in 2021.</p>



<p>Notably, Centessa has been mitigating expected per-share losses. In Q2, the red ink came out to 26 cents per share, better than the expected 49-cent loss. And in Q3, the company disclosed a loss per share of 40 cents, better than the anticipated 52-cent loss. Management will release its Q4 results on March 28.</p>



<p>Currently, covering experts peg CNTA a <a href="https://www.tipranks.com/stocks/cnta/forecast">unanimous strong buy</a> with a $13.33 price target. Again, it could be one of the biotech stocks to consider as a momentum trade.</p>



<h2>Madrigal Pharmaceuticals (MDGL)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/04/pte_biotech_1600-300x169.png" alt="Medical technology network team meeting concept. Doctor hand working smart phone modern digital tablet laptop computer graphics chart interface, sun flare effect photo, PTE"><div>Source: everything possible / Shutterstock.com</div></div><p>Based in West Conshohocken, Pennsylvania, <strong>Madrigal Pharmaceuticals</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/mdgl-stock-quote/"><strong>MDGL</strong></a>) is a clinical-stage biopharmaceutical enterprise focused on the development of therapeutics for the <a href="https://finance.yahoo.com/quote/mdgl/profile">treatment of non-alcoholic steatohepatitis</a> (NASH) in the U.S. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.</p>



<p>As with a few other biotech stocks, MDGL is on the move. Since the January opener, shares gained more than 19%. Essentially, anticipation is running hot that the company could start moving into its growth phase. For the current fiscal year, analysts anticipate that sales could hit $97.04 million on average. Further, the high-side estimate calls for $155.63 million.</p>



<p>Even better, for 2025, they believe $348.93 million is a realistic consensus target for the top line. If so, we&rsquo;re talking about YOY growth of nearly 260%. Further, the high-side 2025 estimate anticipates sales of $531.6 million.</p>



<p>Covering experts rate MDGL a <a href="https://www.tipranks.com/stocks/mdgl/forecast">consensus strong buy</a> with a $369.25 average price target.</p>



<h2>Cytokinetics (CYTK)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/12/shutterstock_1726134715-300x169.png" alt="Biochemical/biotech research scientist team working with microscope"><div>Source: Mongkolchon Akesin / Shutterstock.com</div></div><p>Headquartered in South San Francisco, California, <strong>Cytokinetics</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/cytk-stock-quote/"><strong>CYTK</strong></a>) is a late-stage biopharma focusing on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. <a href="https://www.google.com/finance/quote/CYTK:NASDAQ?hl=en">Per its public profile</a>, the company develops small-molecule drug candidates primarily engineered to impact muscle function and contractility. However, CYTK stock is risky, losing almost 23% of equity value since the start of the year.</p>



<p>Part of the reason for the red ink centers on recent poor earnings performances. For example, in Q4 of last year, the company posted a loss per share of $1.38. However, analysts were anticipating only a loss of 97 cents. It was the same story in Q3, where the loss per share was $1.35 against an expected loss of 74 cents.</p>



<p>However, the current year could be a pivot point. Per the high-side estimate, the company could generate sales of $45.43 million. And on average, analysts believe that in 2025, revenue could be $145.29 million. For context, 2023&rsquo;s top line was only $7.53 million.</p>



<p>Over the next 12 months, covering experts forecast shares <a href="https://www.tipranks.com/stocks/cytk/forecast">reaching $94.63</a>. If so, CYTK is one of the names to consider among biotech stocks.</p>



<h2>Catalyst Pharmaceuticals (CPRX)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/09/cprx-stock-1-300x169.jpg" alt="A magnifying glass zooms in on the website of Catalyst Pharmaceuticals (CPRX)."><div>Source: Pavel Kapysh / Shutterstock.com</div></div><p>Founded in 2002, <strong>Catalyst Pharmaceuticals</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/cprx-stock-quote/"><strong>CPRX</strong></a>) is a commercial-stage biopharma focusing on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular and neurological diseases. <a href="https://www.google.com/finance/quote/CPRX:NASDAQ?hl=en">Per its corporate profile</a>, Catalyst offers Firdapse, an <a href="https://catalystpharma.com/lems-clinical/">amifampridine phosphate tablet</a> for the treatment of patients with the Lambert-Eaton myasthenic syndrome (LEMS). It also offers Ruzurgi for the treatment of pediatric LEMS patients.</p>



<p>Since the start of the year, CPRX stock slipped almost 23%. However, near-term momentum suggests a possible turnaround. Some of the struggles are tied to lackluster earnings performances. From Q1 through Q3 of last year, the average <em>negative</em> earnings surprise came out to 10.23%. That&rsquo;s obviously not great. However, in Q4, the company posted EPS of 31 cents, beating the consensus target of 26 cents.</p>



<p>For the current fiscal year, analysts believe sales of $463.9 million are on tap. If so, that would handily beat last year&rsquo;s haul of $398.2 million. Further, 2025 revenue could be $561.32 million, representing 21% YOY growth.</p>



<p>CPRX enjoys a <a href="https://www.tipranks.com/stocks/cprx/forecast">unanimous strong buy</a> rating with an average price target of $25.51.</p>



<h2>Iovance Biotherapeutics (IOVA)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/10/droplet-test-tube-biotech-1600-3-300x169.jpg" alt="Photo of test tubes and droplet with purple and reddish-orange sunset visual effect, representing biotech"><div>Source: shutterstock.com/Romix Image</div></div><p>Incorporated in 2007, <strong>Iovance Biotherapeutics</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/iova-stock-quote/"><strong>IOVA</strong></a>) develops and commercializes cell therapies using autologous tumor-infiltrating lymphocytes for the treatment of metastatic melanoma and other solid tumor cancers. <a href="https://www.google.com/finance/quote/IOVA:NASDAQ?hl=en">Per its public profile</a>, Iovance offers Amtagvi, a tumor-derived autologous T-cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma.</p>



<p>IOVA happens to be one of the top movers in biotech stocks recently. Since the start of the year, shares gained nearly 72%. Over the past 52 weeks, they more than doubled in value. At first, it seems a curious development. In the first half of 2023, Iovance posted an average positive earnings surprise of nearly 37%. In the second half, the company missed the bottom-line marks.</p>



<p>However, experts believe that in 2024, Iovance will ring up $162.27 million on the top line. And in 2025, this figure could expand to $418.63 million. For context, last year&rsquo;s sales was a measly $1.19 million.</p>



<p>Perhaps best of all, IOVA enjoys a <a href="https://www.tipranks.com/stocks/iova/forecast">strong buy unanimous view</a>. The average price target stands at $26.09, making it one of the intriguing biotech stocks to consider.</p>



<h2>Silence Therapeutics (SLN)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/11/shutterstock_1667119063-300x169.png" alt="Pipette adding fluid to one of several test tubes; biotech NVTA Stock"><div>Source: motorolka / Shutterstock.com</div></div><p>Incorporated in 1994 and based in the U.K., <strong>Silence Therapeutics</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/sln-stock-quote/"><strong>SLN</strong></a>) focuses on the discovery and development of novel ribonucleic acid (<a href="https://investorplace.com/stock-quotes/rna-stock-quote/"><strong>RNA</strong></a>) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. Per its <a href="https://finance.yahoo.com/quote/sln/profile">profile</a>, Silence specializes in its <a href="https://www.reuters.com/markets/companies/SLNCF.PK/">mRNAi GOLD GalNAc Oligonucleotide Discovery platform</a>, which is used to target specific disease-associated genes in the liver.</p>



<p>In addition, its specialized RNA molecules harness the body&rsquo;s natural mechanism of RNA interference, degrading mRNA molecules that encode specific targeted disease-associated proteins in a cell. Specifically, the company is developing SLN360, which is in Phase 2 trials targeting the reduction of excessive levels of lipoprotein.</p>



<p>It&rsquo;s not a profitable enterprise so it ranks among the riskier biotech stocks. However, it&rsquo;s been on a consecutive sales expansion trend since 2019. Currently, its three-year revenue growth rate stands at 47.5%.</p>



<p>Finally, covering analysts rate SLN a <a href="https://www.tipranks.com/stocks/sln/forecast">unanimous strong buy</a> with an average price target of $57.25. That implies growth of almost 151%. What&rsquo;s more, the high-side target seeks a price of $75.</p>



<p><em>On the date of publication, Josh Enomoto</em><em> did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;</em><em>The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;</em><a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank"><em>Publishing Guidelines</em></a><em>.</em><em></em></p>
<div><p>A former senior business analyst for Sony Electronics, Josh Enomoto has helped broker major contracts with Fortune Global 500 companies. Over the past several years, he has delivered unique, critical insights for the investment markets, as well as various other industries including legal, construction management, and healthcare. Tweet him at @EnomotoMedia.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT793992">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/02/wall-street-legend-issues-urgent-ai-code-red/?cid=MKT781156&amp;eid=MKT793990">&ldquo;America&rsquo;s Top Trader&rdquo; Issues A.I. Code Red: Act Now or Miss Out</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793999">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
<p>The post <a href="https://investorplace.com/2024/03/7-biotech-stocks-ready-to-ride-the-sectors-resurgence/">7 Biotech Stocks Ready to Ride the Sector&#8217;s Resurgence</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

7 Biotech Stocks Ready to Ride the Sector's Resurgence

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Sutro Biopharma (STRO – Research Report) and Catalys...

Analysts Are Bullish on Top Healthcare Stocks: Sutro Biopharma (STRO), Catalyst Pharma (CPRX)

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>Biotech has seen its fair share of ups and downs, including a massive surge during the pandemic followed by a considerable dip. However, the industry will never go too far away from center stage as diseases and conditions will always need medicine and technology to treat them. These three strong buy <a href="https://investorplace.com/industries/healthcare/biotech/">biotech stocks</a> are joining the upper ranks of their industry with promising new drugs and encouraging financials that justify serious consideration. </p>



<p>Given the timeline of clinical trials and new releases, these biotech stocks can be some of the best buy-and-hold stocks.&nbsp;</p>



<p>Let&rsquo;s see why investors should add these strong buy biotech stocks to their Q2 watchlist for some promising returns and potential record-setting quarterly numbers this year.</p>



<h2><strong>Axsome Therapeutics (AXSM)</strong></h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/12/axsm-stock-300x169.jpg" alt="A magnifying glass zooms in on the Axsome Therapeutics, Inc. (AXSM) logo"><div>Source: Pavel Kapysh/Shutterstock.com</div></div><p><strong>Axsome Therapeutics </strong>(NASDAQ:<span><a href="https://investorplace.com/stock-quotes/axsm-stock-quote/"><strong>AXSM</strong></a></span>) is a leading producer of treatments for common conditions such as depression, narcolepsy and migraines. Over the last few years, Axsome has had clinical breakthroughs, with the approval of its depression treatment, Auvelity. In addition, Axsome acquired the narcolepsy treatment Sunosi from Jazz Pharmaceuticals in 2022.&nbsp;</p>



<p>Thanks to Auvelity and Sunosi, Axsome saw substantial product <a href="https://axsometherapeuticsinc.gcs-web.com/node/11251/pdf">revenue growth</a> from 2022 to 2023, reaching a 309% year-over-year growth rate. Total revenue also increased five times as much, with Auvelity accounting for $130.1 million and Sunosi $74.8 million of that total.</p>



<p>Axsome is also continuing clinical studies to expand the application of these two drugs to treat <a href="https://www.axsome.com/publications/AAN_2023_SHARP_Study_Topline_040623.pdf">sleep</a> and eating disorders. The company hopes to add more bestsellers, such as <a href="https://www.axsome.com/publications/SLEEP-Poster_2020-Final.pdf">AXS-12</a> to treat narcolepsy and <a href="https://www.axsome.com/publications/AHS_2021_MOVEMENT_poster_4_30_21_FINAL.pdf">AXS-07</a> to treat migraines.</p>



<p>With Axsome&rsquo;s current momentum and the announcement of results from its ongoing trials, this stock is a must for your watchlist this year.</p>



<h2><strong>Krystal Biotech (KRYS)</strong></h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/10/droplet-test-tube-biotech-1600-3-300x169.jpg" alt="Photo of test tubes and droplet with purple and reddish-orange sunset visual effect, representing biotech"><div>Source: shutterstock.com/Romix Image</div></div><p>Known for its drug Vyjuvek, a dystrophic epidermolysis bullosa (DEB) treatment, <strong>Krystal Biotech</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/krys-stock-quote/"><strong>KRYS</strong></a></span>) has risen to the top of the biotech ranks since last year. Following its FDA approval in May last year, Vyjuvek generated <a href="https://ir.krystalbio.com/news-releases/news-release-details/krystal-biotech-announces-fourth-quarter-and-full-year-2023">$50.7</a> million in product revenue for Krystal in 2023.</p>



<p>More than $40 million of that product revenue was generated in <a href="https://ir.krystalbio.com/news-releases/news-release-details/krystal-biotech-announces-fourth-quarter-and-full-year-2023">Q4</a> alone, making that number even more impressive. You can probably guess, but this report exceeded expectations and earned Krystal its current position in the market.</p>



<p>Spreading its reach into <a href="https://ir.krystalbio.com/static-files/cee89ff1-0c7a-453e-b283-fed2b829f652">treatments</a> for respiratory conditions, Krystal is currently in phase 1-2 clinical trials for cystic fibrosis (KB407) and alpha-a antitrypsin deficiency (KB408). Other trials include oncology, dermatology and ophthalmology treatments.&nbsp;</p>



<p>Krystal Biotech is another company surging to the top of biotech with record sales and excellent prospects for continued growth this year.</p>



<h2><strong>Catalyst Pharmaceuticals (CPRX)</strong></h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/09/cprx-stock-1-300x169.jpg" alt="A magnifying glass zooms in on the website of Catalyst Pharmaceuticals (CPRX)."><div>Source: Pavel Kapysh / Shutterstock.com</div></div><p><strong>Catalyst Pharmaceuticals</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/cprx-stock-quote/"><strong>CPRX</strong></a></span>) has had ups and downs since last year but has managed to find its way to the top ranks of biotech time and time again. After coming off of an immaculate Q4 with an 82% increase in <a href="https://ir.catalystpharma.com/news-releases/news-release-details/catalyst-pharmaceuticals-reports-strong-fourth-quarter-and-full">revenue</a> and a year-over-year jump of 85.9% in yearly revenue.&nbsp;</p>



<p>Not to mention an earnings beat, with adjusted EPS of $0.63. How did they do it? The answer is the company&rsquo;s two hot-selling products, Fycompa and Firdapse. Fycompa is an anti-seizure medication and Firapse is used to treat Lambert-Eaton myasthenic syndrome (LEMS), an autoimmune condition common in lung cancer patients.<br>Both treatments had record sales in 2023, generating $396.5 million in combined product revenue. With current momentum, there is no better time to give Catalyst the attention it is due as a top pick for biotech stocks this year.</p>



<p><em>On the date of publication, Joel Lim did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.</em></p>
<div><p>Joel Lim is a finance freelance writer who writes content for several companies like LTSE and Realtor, along with financial publications, including Mises Institute and Foundation for Economic Education.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
<p>The post <a href="https://investorplace.com/2024/03/3-strong-buy-biotech-stocks-to-add-to-your-q2-must-watch-list/">3 Strong Buy Biotech Stocks to Add to Your Q2 Must-Watch List</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

3 Strong Buy Biotech Stocks to Add to Your Q2 Must-Watch List

Solid Biosciences gets FDA rare pediatric disease status for DMD therapy

Top buy-rated stocks and sell-rated stocks within Health Care - Citi

Catalyst Pharmaceuticals: Revenue Growth Lagging Expense Growth (Rating Downgrade)

AXSM

BLTE

CAPR

CNTA

CYTK

EXEL

IART

INCY

IOVA

KRMD

KRYS

LXRX

MDGL

NYXH

OSUR

PODD

PTCT

RCUS

RHHBY

SDGR

SLDB

SRPT

STRO

TECH

Press Releases

Catalyst Pharmaceuticals Announces Publication of Santhera Pharmaceutical's VISION-DMD Vamorolone (AGAMREE®) Study Results in the Peer-Reviewed Journal Neurology

Catalyst Pharmaceuticals to Present at MDA Clinical & Scientific Conference Details of Registry for Study of Long-Term Safety and Quality of Life in Duchenne Muscular Dystrophy Patients Treated with AGAMREE

Health Care

Catalyst Pharmaceuticals Reports Strong Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Catalyst Pharmaceuticals to Participate at the Barclays 26th Annual Global Healthcare Conference

Catalyst Pharmaceuticals Announces AGAMREE® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (DMD)

Santhera's Partner Catalyst Pharmaceuticals Launches AGAMREE® (Vamorolone) in the United States

Opinion

Thinking about buying stock in Analog Devices,Catalyst Pharmaceuticals, QuickLogic, Synopsys, or Pagaya Technologies?

Thinking about buying stock in Praxis Precision Medicines, Safety Shot, Catalyst Pharmaceuticals, Adicet Bio, or Exscientia?

Catalyst Pharmaceuticals to Participate in the 2024 Cantor Virtual Muscular Dystrophy Symposium

Catalyst Pharmaceuticals Announces Support for the Inaugural Lambert-Eaton Myasthenic Syndrome (LEMS) Awareness Day